Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 183
Filtrar
1.
Indian J Pharmacol ; 56(3): 220-223, 2024 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-39078187

RESUMO

ABSTRACT: Acitretin is a synthetic, second-generation retinoid mainly used for the treatment of Darier's disease (DD), which impacts biological processes by binding to a nuclear receptor from the corticosteroid/thyroid receptor superfamily, thereby altering gene expression. Our report outlines the case of a 41-year-old male patient who has received a clinical diagnosis of DD and does not exhibit any other coexisting comorbidities, who developed hypothyroidism posttreatment with acitretin, an unusual and rare side effect of the drug. His baseline routine investigations fell within normal limits before the initiation of acitretin. Acitretin-induced hypothyroidism was treated with thyroxine. Although a good therapeutic response was seen with acitretin, it could not be continued due to the development of side effects and was continued on topical therapy. This case emphasizes the likelihood of adverse effects linked to therapeutic levels of acitretin in patients without any prior history and signifies the critical importance of consistent blood monitoring throughout drug therapy.


Assuntos
Acitretina , Doença de Darier , Hipotireoidismo , Ceratolíticos , Humanos , Acitretina/efeitos adversos , Acitretina/uso terapêutico , Masculino , Adulto , Hipotireoidismo/induzido quimicamente , Hipotireoidismo/tratamento farmacológico , Doença de Darier/tratamento farmacológico , Doença de Darier/induzido quimicamente , Ceratolíticos/efeitos adversos , Ceratolíticos/uso terapêutico , Tiroxina/uso terapêutico
2.
Clin Exp Dermatol ; 49(9): 1052-1055, 2024 Aug 22.
Artigo em Inglês | MEDLINE | ID: mdl-38620055

RESUMO

Acitretin, commonly used for severe psoriasis and keratinocyte carcinoma chemoprevention in high-risk patients, is contraindicated in patients with end-stage renal disease (ESRD) on haemodialysis (HD). However, these patients often lack medication choices and in certain clinical scenarios the benefits of acitretin may outweigh the potential risks. We identified 24 patients with ESRD on HD undergoing acitretin treatment from the Duke and Vanderbilt University Medical Centers. While adverse effects were common, they were not a frequent cause of treatment discontinuation among patients. We also found no association between acitretin treatment and hospital admissions or mortality. Lastly, we found statistically significant increases in alkaline phosphatase (ALP; P = 0.03) and total bilirubin (P < 0.001) when patients were receiving acitretin and HD compared with baseline. However, there was no dose dependency or temporal association with acitretin or HD initiation. Based on these preliminary findings, we find that acitretin may safely be used in patients receiving HD, with close monitoring of ALP and bilirubin.


Assuntos
Acitretina , Bilirrubina , Ceratolíticos , Falência Renal Crônica , Psoríase , Diálise Renal , Humanos , Acitretina/efeitos adversos , Acitretina/uso terapêutico , Diálise Renal/efeitos adversos , Feminino , Masculino , Falência Renal Crônica/complicações , Falência Renal Crônica/terapia , Pessoa de Meia-Idade , Psoríase/tratamento farmacológico , Psoríase/complicações , Ceratolíticos/efeitos adversos , Ceratolíticos/uso terapêutico , Bilirrubina/sangue , Idoso , Fosfatase Alcalina/sangue , Adulto , Estudos Retrospectivos
3.
Indian J Pharmacol ; 53(5): 388-390, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34854408

RESUMO

Psoriatic involvement of nails manifests in the form of irregular, deep and large pits, splinter hemorrhages, subungual hyperkeratosis, oil drop spot, and onycholysis of the nail bed. Retinoids are one of the treatment modalities for nail psoriasis. Pseudogynecomastia is an uncommonly reported side effect of retinoids. We hereby describe an 11-year-old adolescent who developed pseudogynecomastia posttreatment with acitretin for nail psoriasis.


Assuntos
Acitretina/efeitos adversos , Ginecomastia/diagnóstico , Ceratolíticos/efeitos adversos , Doenças da Unha/tratamento farmacológico , Psoríase/tratamento farmacológico , Criança , Diagnóstico Diferencial , Ginecomastia/induzido quimicamente , Humanos , Masculino
4.
Dermatol Online J ; 27(7)2021 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-34391333

RESUMO

Periungual pyogenic granulomas are benign vascular tumors that present as painful, round, spontaneously bleeding lesions composed of rapidly proliferating capillaries and excess tissue. The vast majority of pyogenic granulomas are caused by physical trauma or infectious agents and they may resolve spontaneously. Herein, we highlight a very rare case of periungual pyogenic granulomas induced by the regularly prescribed oral retinoid acitretin during treatment for congenital palmoplantar keratoderma. This unique case showed that it is feasible to continue acitretin therapy in the presence of pyogenic granuloma development if proper dose reduction and topical therapies are utilized. The patient's lesions resolved within two weeks of this protocol's initiation and the pyogenic granulomas did not recur over the course of a six-month follow-up observation period. In addition, we performed a systematic review of the literature using PubMed databases for the clinical features and treatments in other reported acitretin-induced pyogenic granuloma cases; we compiled a comprehensive list of other prescription drugs known to cause pyogenic granulomas up-to-date.


Assuntos
Acitretina/efeitos adversos , Granuloma Piogênico/induzido quimicamente , Ceratolíticos/efeitos adversos , Doenças da Unha/induzido quimicamente , Acitretina/administração & dosagem , Administração Oral , Adulto , Antibacterianos/administração & dosagem , Clobetasol/administração & dosagem , Glucocorticoides/administração & dosagem , Humanos , Ceratodermia Palmar e Plantar/tratamento farmacológico , Ceratolíticos/administração & dosagem , Masculino , Mupirocina/administração & dosagem
5.
J Cosmet Dermatol ; 19(5): 1016-1020, 2020 May.
Artigo em Inglês | MEDLINE | ID: mdl-32112510

RESUMO

BACKGROUND: Due to the ever-increasing demands for the personalized care, people seek for the tailored management according to the accurate identification of their skin type. The Baumann Skin Type Indicator, which was proposed by Leslie Baumann, is composed of four parameters: oily or dry, resistant or sensitive, pigmented or nonpigmented, and wrinkled or tight. Among these, oily sensitive skin experiences significant discomfort and resists ordinary treatment. AIMS: In this article, we will review the clinical manifestations, underlying pathogenesis and recommendations on treatment options that may be utilized to help patients with oily sensitive skin. PATIENTS/METHODS: Literature search was conducted using PubMed. The literature concerning Baumann Skin Type Indicator and oily sensitive skin type were considered. RESULTS: Oily sensitive (OS)-type skin is a complex of oily and sensitive skin that causes significant discomfort and undergoes stubborn resistance to treatments. Sebum dysfunction and hypersensitivity may play a key role in the development of sensitive skin. Considering the pathogenesis of OS-type skin, treatment should focus on both seborrhea and hypersensitivity. CONCLUSION: Clinicians can effectively treat the oily sensitive skin by understanding underlying pathogenesis of it. Further investigations are necessary to reach a consensus on the basic pathophysiology and optimal management guidelines for oily sensitive skin.


Assuntos
Acne Vulgar/terapia , Técnicas Cosméticas/normas , Dermatite de Contato/terapia , Dermatite Seborreica/terapia , Rosácea/terapia , Acne Vulgar/fisiopatologia , Administração Cutânea , Administração Oral , Antibacterianos/administração & dosagem , Toxinas Botulínicas/administração & dosagem , Toxinas Botulínicas/efeitos adversos , Técnicas Cosméticas/efeitos adversos , Dermatite de Contato/fisiopatologia , Dermatite Seborreica/fisiopatologia , Humanos , Injeções Intradérmicas , Isotretinoína/administração & dosagem , Isotretinoína/efeitos adversos , Ceratolíticos/administração & dosagem , Ceratolíticos/efeitos adversos , Guias de Prática Clínica como Assunto , Rosácea/fisiopatologia , Sebo/metabolismo , Pele/metabolismo , Pele/fisiopatologia , Resultado do Tratamento
6.
JAMA Dermatol ; 156(3): 303-311, 2020 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-31913405

RESUMO

Importance: Podophyllotoxin is an antimitotic agent primarily used in the local treatment of anogenital warts. Data that enable the assessment of the fetal safety of podophyllotoxin use during pregnancy are lacking. Objective: To investigate the association between local podophyllotoxin exposure during pregnancy and risk of adverse fetal outcomes. Design, Setting, and Participants: This cohort study obtained individual-level pregnancy data from various nationwide registries in Denmark from the study period of January 1, 1997, through December 31, 2016, resulting in a cohort of 1 650 649 pregnancies. Pregnancies with multiple records on overlapping dates and pregnancy records with implausible or missing information on gestational age were excluded. Local podophyllotoxin-exposed pregnancies were compared with unexposed pregnancies and matched in a 1:10 ratio according to propensity scores on a wide set of baseline characteristics. Five distinct study cohorts were constructed, one for each outcome analysis. Sensitivity analyses included a comparison of podophyllotoxin-exposed pregnancies with pregnancies with podophyllotoxin use only before pregnancy onset. Data analyses were performed from April 27, 2019, to June 26, 2019. Exposures: Filled prescription for local podophyllotoxin. Main Outcomes and Measures: Primary outcomes were major birth defects and spontaneous abortions. Secondary outcomes were preterm births, small-for-gestational-age (SGA) size, and stillbirths. Logistic regression was used to estimate the prevalence odds ratios (ORs) of major birth defects, preterm births, and SGA size, and Cox proportional hazards regression modeling was used to estimate hazard ratios (HRs) of spontaneous abortions and stillbirths. Results: This study included 9229 pregnancies (mean [SD] maternal age at pregnancy onset, 27.7 [5.2] years) for the analyses of major birth defects and 18 590 pregnancies (mean [SD] maternal age at pregnancy onset, 26.4 [6.0] years) for the analyses of spontaneous abortions. Among the podophyllotoxin-exposed pregnancies, 29 infants (3.5%) were diagnosed with major birth defects, compared with 286 (3.4%) among the unexposed pregnancies. A total of 141 podophyllotoxin-exposed pregnancies (8.3%) ended in spontaneous abortion, compared with 1626 (9.6%) among the unexposed pregnancies. No statistically significant associations were found between podophyllotoxin exposure during pregnancy and major birth defects (prevalence odds ratio [OR], 1.02 95% CI, 0.69-1.50), spontaneous abortions (HR, 0.87; 95% CI, 0.73-1.04), preterm births (prevalence OR, 1.08; 95% CI, 0.86-1.35), SGA size (prevalence OR, 1.01; 95% CI, 0.85-1.22), or stillbirths (HR, 0.58; 95% CI, 0.18-1.86). Sensitivity analyses of the primary outcomes achieved similar results. Conclusions and Relevance: Findings from this study suggest that podophyllotoxin use during pregnancy may be safe, as it did not appear to be associated with an increased risk of adverse fetal outcomes. These findings may help guide clinicians, patients, and drug regulatory authorities when prescribing podophyllotoxin.


Assuntos
Condiloma Acuminado/tratamento farmacológico , Ceratolíticos/efeitos adversos , Podofilotoxina/efeitos adversos , Resultado da Gravidez , Administração Tópica , Adulto , Estudos de Coortes , Dinamarca , Feminino , Humanos , Recém-Nascido , Ceratolíticos/administração & dosagem , Podofilotoxina/administração & dosagem , Gravidez , Complicações Infecciosas na Gravidez/tratamento farmacológico , Sistema de Registros , Adulto Jovem
7.
Dermatol Surg ; 46(9): 1204-1209, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-31743246

RESUMO

BACKGROUND: Chemical peels are applied to the face and neck to improve rhytides and the photoaged appearance of the skin. Peels can be applied to different skin depths depending on the types of chemicals, the volume of solution, and the amount of pressure or friction applied. If a peel is applied too superficially, rhytides will not be removed. If a peel is applied too deeply, scarring or hypopigmentation could occur. OBJECTIVE: To create face and neck depth maps for chemical peeling, which can guide safety when removing rhytides and improving the skin's appearance. MATERIALS AND METHODS: A multicenter retrospective review of records was conducted of patients who underwent phenol-croton oil peeling, from January 1, 2018, to December 31, 2018. Information was collected on facial and neck cosmetic units peeled, peel formula and strength used, outcomes, and complications. RESULTS: A total of 410 patients received deep peels. Two depth maps were created that corresponded to the most common patterns of deep chemical peel applications. CONCLUSION: Different areas of the face and neck are treated with different chemical peel application depths to safely improve rhytides and appearance. Depth maps are created to balance safety and efficacy.


Assuntos
Abrasão Química/métodos , Dermabrasão/métodos , Ceratolíticos/administração & dosagem , Administração Cutânea , Adulto , Idoso , Idoso de 80 Anos ou mais , Abrasão Química/efeitos adversos , Óleo de Cróton/administração & dosagem , Óleo de Cróton/efeitos adversos , Dermabrasão/efeitos adversos , Face/anatomia & histologia , Feminino , Humanos , Ceratolíticos/efeitos adversos , Masculino , Pessoa de Meia-Idade , Pescoço/anatomia & histologia , Fenol/administração & dosagem , Fenol/efeitos adversos , Estudos Retrospectivos , Pele/anatomia & histologia , Pele/efeitos dos fármacos , Envelhecimento da Pele , Resultado do Tratamento
8.
Dermatol Surg ; 45(11): 1394-1400, 2019 11.
Artigo em Inglês | MEDLINE | ID: mdl-31464703

RESUMO

BACKGROUND: To study and compare the therapeutic efficacy and side effects of a 35% glycolic acid (GA) full face peel alone or in combination with a 10% or 20% trichloroacetic acid (TCA) spot peel for facial melasma. METHODS: Thirty patients with facial melasma were randomly divided into 3 equal Groups A, B, and C. Group A was treated with a 35% GA full-face peel, Group B and C with 35% GA full-face peel followed by a 10% and 20% TCA spot peel respectively once every 15 days. Four peels were performed once every 15 days. The response to the treatment was evaluated by the percentage reduction in melasma area severity index (MASI) scoring. RESULTS: All 3 groups had significant reduction of MASI, but there was no significant difference between the groups. Group A had minimum side effects. CONCLUSION: Chemical peels with GA alone or in combination with TCA do result in a significant improvement in melasma, but the combination of the peels in the same sitting does not seem to have any additive or synergistic effect while they may increase the side effects.


Assuntos
Abrasão Química/métodos , Glicolatos/administração & dosagem , Ceratolíticos/administração & dosagem , Melanose/terapia , Ácido Tricloroacético/administração & dosagem , Adulto , Abrasão Química/efeitos adversos , Terapia Combinada , Face , Feminino , Glicolatos/efeitos adversos , Humanos , Ceratolíticos/efeitos adversos , Masculino , Pessoa de Meia-Idade , Pele/efeitos dos fármacos , Resultado do Tratamento , Ácido Tricloroacético/efeitos adversos , Adulto Jovem
9.
Hautarzt ; 70(7): 535-546, 2019 Jul.
Artigo em Alemão | MEDLINE | ID: mdl-31197390

RESUMO

In this article, a comprehensive, yet introductory overview on chemexfoliation is given. The molecular mechanisms for selected indications are exemplified and the prerequisites, necessary precautions as well as potential complications are addressed. Finally, selected available superficial peeling substances are presented and the principal peeling procedure is outlined briefly.


Assuntos
Erupções Acneiformes/terapia , Abrasão Química/métodos , Ceratolíticos/uso terapêutico , Ceratose/terapia , Abrasão Química/efeitos adversos , Dermatologia , Humanos , Ceratolíticos/efeitos adversos , Avaliação de Processos e Resultados em Cuidados de Saúde
11.
Dermatol Surg ; 45(10): 1245-1252, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-30893166

RESUMO

BACKGROUND: Striae gravidarum is a common skin condition resulting after pregnancy, caused by fibroblast dysfunction. Although not considered a disease, it may be considered cosmetically unpleasant to sufferers and remains as a therapeutic challenge to date. OBJECTIVE: To evaluate the efficacy and safety of a sublative bipolar fractional radiofrequency (FRF) system, associated with 0.1% topical tretinoin, in treating striae gravidarum. MATERIALS AND METHODS: Eighteen Chinese women with striae gravidarum on the abdomen were enrolled in the study. The target area of each patient was divided into 4 sites randomly: control, tretinoin, FRF, and tretinoin and FRF. Fractional RF was used 3 times, with 3-month intervals. Changes to striae gravidarum were evaluated through subjective scaling and objective measures, using both high-frequency ultrasound and histological study. RESULTS: Both subjective assessment and skin thickness differences demonstrated significant improvement in the combination site (p < .001). Average optical density and density percentage of neocollagen and elastic fibers were also markedly increased in the combination site (p < .05). The adverse effects of FRF were limited to mild pain and transient erythema, edema, and microcrusts. CONCLUSION: The combined therapy of FRF and topical tretinoin may be a potential method in treating striae gravidarum, with satisfactory efficacy and limited side effects.


Assuntos
Ceratolíticos/administração & dosagem , Complicações na Gravidez/terapia , Terapia por Radiofrequência/métodos , Estrias de Distensão/terapia , Tretinoína/administração & dosagem , Adulto , Eritema/diagnóstico , Eritema/etiologia , Feminino , Humanos , Ceratolíticos/efeitos adversos , Pessoa de Meia-Idade , Dor/diagnóstico , Dor/etiologia , Medição da Dor , Satisfação do Paciente , Projetos Piloto , Gravidez , Complicações na Gravidez/diagnóstico por imagem , Terapia por Radiofrequência/efeitos adversos , Terapia por Radiofrequência/instrumentação , Pele/diagnóstico por imagem , Pele/efeitos dos fármacos , Pele/efeitos da radiação , Creme para a Pele/administração & dosagem , Creme para a Pele/efeitos adversos , Estrias de Distensão/diagnóstico por imagem , Resultado do Tratamento , Tretinoína/efeitos adversos , Ultrassonografia
15.
J Cutan Med Surg ; 21(3_suppl): 2S-12S, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28952335

RESUMO

BACKGROUND: Acitretin has been used for the treatment of severe psoriasis for over 20 years. OBJECTIVE: The current project was conceived to optimise patient care by recognising the role acitretin can play in the treatment of patients with psoriasis and those with other disorders of keratinisation. METHODS: A literature review was conducted to explore the role of acitretin and to assess its value for dermatologic disorders other than severe psoriasis. A panel of Canadian dermatologists developed a clinical pathway using a case-based approach, focusing on specific patient features. RESULTS: The clinical pathway covers plaque psoriasis with hyperkeratotic plantar disease, palmoplantar pustulosis, hyperkeratotic hand dermatitis, lichen planus, lamellar ichthyosis, and hidradenitis suppurativa. CONCLUSION: The recommendations in our clinical pathway reflect the current use of acitretin in Canada for severe psoriasis and other disorders of keratinisation.


Assuntos
Acitretina/uso terapêutico , Ceratolíticos/uso terapêutico , Dermatopatias/tratamento farmacológico , Acitretina/efeitos adversos , Contraindicações de Medicamentos , Hidradenite Supurativa/tratamento farmacológico , Humanos , Ictiose Lamelar/tratamento farmacológico , Ceratodermia Palmar e Plantar/tratamento farmacológico , Ceratolíticos/efeitos adversos , Líquen Plano/tratamento farmacológico , Seleção de Pacientes , Psoríase/tratamento farmacológico
16.
J Cosmet Laser Ther ; 19(6): 347-352, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28489473

RESUMO

BACKGROUND: Treatment for recalcitrant plantar warts remains a continuing challenge as the options for treatment have differing levels of success. long-pulsed Nd:YAG laser is considered a good treatment modality in resistant plantar warts. On the other hand, high cure rates have been reported with a topical proprietary formulation consisting of 1% cantharidin, 5% podophyllotoxin, 30% salicylic acid. AIM: To compare the efficacy of 1% cantharidin, 20% podophylline resin and 30% salicylic acid (CPS) versus long-pulsed Nd:YAG laser in the treatment of recalcitrant plantar warts. METHODS: This study included 30 patients with single or multiple recalcitrant plantar warts; patients were assigned to two groups: the first group included 15 patients with 71 recalcitrant plantar warts who were treated by long-pulsed Nd:YAG laser (group I) and the second group included 15 patients with 78 recalcitrant plantar warts who received CPS (group II). The diagnosis of plantar warts was made by clinical examination. RESULTS: Fourteen patients (93%) were completely cleared of their warts with topical CPS, while 11 patients (73%) showed complete clearance with long-pulsed Nd:YAG laser with statistically significant difference between the two groups. CONCLUSION: Topical CPS is safe and efficacious and represents a promising therapeutic modality than long-pulsed Nd:YAG laser in the treatment of recalcitrant plantar warts.


Assuntos
Ceratolíticos/uso terapêutico , Lasers de Estado Sólido/uso terapêutico , Terapia com Luz de Baixa Intensidade/métodos , Verrugas/tratamento farmacológico , Verrugas/radioterapia , Adulto , Cantaridina/uso terapêutico , Combinação de Medicamentos , Feminino , Humanos , Ceratolíticos/administração & dosagem , Ceratolíticos/efeitos adversos , Lasers de Estado Sólido/efeitos adversos , Terapia com Luz de Baixa Intensidade/efeitos adversos , Masculino , Pessoa de Meia-Idade , Podofilotoxina/uso terapêutico , Ácido Salicílico/uso terapêutico
19.
Br J Dermatol ; 176(6): 1446-1455, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28112799

RESUMO

BACKGROUND: Drugs that are currently used in the treatment of psoriasis are associated with drawbacks such as rapid recrudescence, high costs and unwanted side-effects. Oxymatrine has a long history of clinical use in the treatment of hepatitis and cancer in China. OBJECTIVES: To explore the efficacy and safety of intravenous oxymatrine in patients with severe plaque psoriasis. METHODS: A total of 67 patients were randomly allocated to receive oxymatrine injections (0.6 g per day for 8 weeks) or acitretin capsules (0.75 mg kg-1 per day from week 0 to week 2 and 20-30 mg per day from week 3 to week 8) and followed up for another 24 weeks. The primary end point was the percentage of patients with ≥ 50% reduction of Psoriasis Area and Severity Index (PASI 50) at week 32. The secondary end points included the skin classification grade and the Dermatology Quality of Life Index (DLQI) score. Side-effects were recorded throughout the whole study to assess the safety profile. RESULTS: Treatment with oxymatrine or acitretin for 8 weeks significantly decreased PASI score, skin classification grade and DLQI score (P < 0.001), with no significant differences between the oxymatrine and acitretin groups in terms of PASI 50. However, at week 32, the relapse rate in the oxymatrine group was significantly lower than that of the acitretin group (P < 0.001). Moreover, while there was an increase in the number of patients with metabolic abnormalities in the acitretin group, a significant reduction was observed in the oxymatrine group. Furthermore, rates of adverse reactions were significantly decreased in the oxymatrine group compared with that of the acitretin group (P < 0.001). CONCLUSIONS: Treatment with oxymatrine effectively ameliorated severe plaque psoriasis, and was accompanied by only minor adverse effects.


Assuntos
Alcaloides/administração & dosagem , Ceratolíticos/administração & dosagem , Psoríase/tratamento farmacológico , Quinolizinas/administração & dosagem , Acitretina/administração & dosagem , Acitretina/efeitos adversos , Adulto , Alcaloides/efeitos adversos , Esquema de Medicação , Feminino , Humanos , Injeções Intravenosas , Ceratolíticos/efeitos adversos , Masculino , Qualidade de Vida , Quinolizinas/efeitos adversos , Prevenção Secundária , Método Simples-Cego , Resultado do Tratamento
20.
Life Sci ; 168: 24-27, 2017 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-26757104

RESUMO

AIMS: Pigmented lesions such as of seborrheic keratosis and senile lentigo, which are commonly seen on skin of people>50years of age, are considered unattractive and disfiguring because of their negative psychological impact. Drug therapy using all-trans retinoic acid (ATRA) is an attractive option for self-treatment at home. We have developed an ATRA-loaded microneedle patch (ATRA-MN) and confirmed the pharmacological effects of ATRA-MN application in mice. Here, we describe a clinical study to evaluate the safety and efficacy of ATRA-MN in subjects with seborrheic keratosis or senile lentigo. MAIN METHODS: ATRA-MN was applied to the lesion site of each subject for 6h once per week for 4weeks. The skin irritation reaction was scored to assess adverse reactions and blood tests were performed to evaluate the presence of systemic adverse reactions. To assess the treatment effect using ATRA-MN, the desquamation and whitening ability of the investigational skin was observed. KEY FINDINGS: Desquamation of the stratum corneum was observed following four ATRA-MN applications at 1-week intervals, but ATRA-MN applications did not induce severe local or systemic adverse effects. SIGNIFICANCE: These results showed that ATRA-MN treatment is promising as a safe and effective therapy for seborrheic keratosis and senile lentigo.


Assuntos
Ceratolíticos/uso terapêutico , Ceratose Seborreica/tratamento farmacológico , Lentigo/tratamento farmacológico , Pele/efeitos dos fármacos , Adesivo Transdérmico , Tretinoína/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Ceratolíticos/administração & dosagem , Ceratolíticos/efeitos adversos , Ceratose Seborreica/patologia , Lentigo/patologia , Masculino , Pessoa de Meia-Idade , Agulhas , Pele/metabolismo , Pele/patologia , Adesivo Transdérmico/efeitos adversos , Tretinoína/administração & dosagem , Tretinoína/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA